Department of Cranio-Maxillofacial Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Oral and Maxillofacial Surgery, School of Life, Dentistry at Niigata, The Nippon Dental University, Niigata, Japan.
J Biomed Mater Res A. 2017 Oct;105(10):2655-2661. doi: 10.1002/jbm.a.36125. Epub 2017 Jun 15.
Recent research has demonstrated that recombinant human bone morphogenetic protein 9 (rhBMP9) has been considered the most osteoinductive growth factor of the BMP-family. In the present study, rhBMP9 was investigated for its influence in combination with two biomaterials for bone regenerative medicine. Either porcine-derived collagen membrane (CM) or deproteinized bovine bone mineral (DBM) combined with 20 µg of rhBMP9 were implanted in 6 mm rabbit calvarial defects. Bone augmentation was evaluated by microCT and histomorphometry at 8 weeks post-surgery. Both CM + rhBMP9 and DBM + rhBMP9 groups significantly promoted mineralized tissue volume (microCT) and area, new bone height and area (histomorphometric measurements) when compared to CM and DBM alone groups or control (empty). All specimens in the CM + rhBMP9 group but not all in the DBM + rhBMP9 group induced a complete horizontal bone defect closure. Multinucleated giant cells (MNGCs) were observed directly in contact with DBM surfaces irrespective of rhBMP9, whereas CM was generally not associated to the presence of MNGCs. When combined with rhBMP9, DBM augmented a larger volume of mineralized tissue (including the mineralized bone graft), whereas CM induced greater volume of native host bone. While DBM in combination with rhBMP9 induced higher mineralized tissue mostly associated with the bone grafting material, CM may have presented preferable results based on a higher horizontal defect closure with a faster regeneration of host new bone. The effect of including collagen within the carrier system of rhBMP9 on bone regeneration justifies further evaluation of this combination procedure in larger animal models. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 2655-2661, 2017.
最近的研究表明，重组人骨形态发生蛋白 9（rhBMP9）已被认为是 BMP 家族中最具成骨活性的生长因子。在本研究中，研究了 rhBMP9 与两种用于骨再生医学的生物材料联合使用的情况。将 20µg 的 rhBMP9 与猪源胶原膜（CM）或脱蛋白牛骨矿物质（DBM）结合植入 6mm 兔颅骨缺损。术后 8 周通过 microCT 和组织形态计量学评估骨增量。与 CM 和 DBM 单独组或空白对照（空）相比，CM+rhBMP9 和 DBM+rhBMP9 组均显著增加了矿化组织体积（microCT）和面积、新骨高度和面积（组织形态计量学测量）。CM+rhBMP9 组的所有标本均诱导了完全的水平骨缺损闭合，但并非 DBM+rhBMP9 组的所有标本均如此。无论 rhBMP9 存在与否，均观察到多核巨细胞（MNGCs）直接与 DBM 表面接触，而 CM 通常与 MNGCs 的存在无关。当与 rhBMP9 结合使用时，DBM 增加了更多的矿化组织体积（包括矿化骨移植物），而 CM 则增加了更多的宿主固有骨体积。虽然 DBM 与 rhBMP9 联合使用可诱导更高的矿化组织，主要与骨移植材料相关，但 CM 可能具有更好的效果，因为它具有更高的水平缺损闭合率和更快的宿主新骨再生。在 rhBMP9 的载体系统中包含胶原对骨再生的影响证明了在更大的动物模型中进一步评估这种联合程序的合理性。© 2017 Wiley Periodicals, Inc. J 生物材料研究杂志 A 部分：105A：2655-2661，2017。
